Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […]
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) and Novavax (NASDAQ:NVAX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations. Earnings and Valuation This table compares Harpoon Therapeutics and Novavax’s […]
Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) were down 3.7% during trading on Monday . The company traded as low as $0.58 and last traded at $0.59. Approximately 352,029 shares were traded during trading, a decline of 15% from the average daily volume of 413,621 shares. The stock had previously closed at $0.61. […]
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor. | June 19, 2023